The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The relative efficacy and safety of dabigatran etexilate and warfarin have been evaluated in two head-to-head, phase III, treatment of acute venous thromboembolism (VTE) trials, and one extended prophylaxis trial, in patients with high risk of recurrent VTE. Dabigatran etexilate demonstrated similar efficacy to warfarin, and was associated with a reduced risk of major or clinically relevant bleeds. Based on results of these trials, and real-life disease prognosis following discontinuation of anticoagulation treatment, we evaluated the cost-utility of dabigatran etexilate compared with warfarin in six months anticoagulation, and in extended, up to 24 months anticoagulation, in patients with acute VTE, acute deep-vein thrombosis (DVT) or acute, symptomatic, pulmonary embolism (PE). Costs were analysed from the perspective of the National Health Services (NHS) and Public Social Services (PSS) in England and Wales. Outcomes were quantified in quality-adjusted life years (QALY). The estimated incremental, lifetime cost/QALY gain following acute, symptomatic VTE (DVT or PE) was £1,252/QALY when dabigatran etexilate or warfarin were administered for up to six months treatment. In treatment of acute, symptomatic PE and in DVT respective ratios were £1,767/QALY and £1,075/QALY. In extended, up to 24 months anticoagulation, dabigatran etexilate projected costs/QALY of £8,242/QALY, when compared with warfarin. Results obtained herein were robust across a number of sensitivity analyses a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All of them suggested that DOACs are costeffective relative to VKA. 100,104-116”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [106]
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544 · cited 2×
“A unique algorithm (22) allows attribution of health-state utility “weights”, from the general population, to the individual patient scores.”
BackgroundOral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583 · cited 13×
“The pooled probability of recurrent VTE and VTE-related death, and the pooled probability of MCRB in the warfarin arm served as the baseline probability of events in our model.”
BackgroundMethodInfluentialBüller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324 · cited 3×
“68 % (189/2462), log-transformed with respect to time (7); l –18-months incidence of major or clinically relevant non-major bleeding event: 10.”
BackgroundEdoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
Pengo, V., Lensing, A. W. A., Prins, M. H., Marchiori, A., Davidson, B. L., Tiozzo, F., Albanese, P., Biasiolo, A., Pegoraro, C., Iliceto, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032274 · Cited by 1,828 · cited 2×
“(20); no incident cases occurred beyond two years and patients were followed-up for a median of 94.”
BackgroundApixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Research works printed but not linked: 1
- Prandoni, 1997, Haematologica, 82, 423
Cited by
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
“All of them suggested that DOACs are costeffective relative to VKA.(100,104-116)”
BackgroundDOACs – advances and limitations in real world
Lee, L. H. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0111-3 · Cited by 96
“positive cost savings and cost-effectiveness of DOACs in routine clinical practices [59–61], these may not be ap-”
BackgroundMai, V., Bertoletti, L., Cucherat, M., Mainbourg, S., Grangé, C., Provencher, S., & Lega, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214134 · Cited by 35
Le, P. N. B., Martinez, K. A., Pappas, M. A., & Rothberg, M. B. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13687 · Cited by 32
Armstrong, N., Büyükkaramikli, N., Penton, H., Riemsma, R., Wetzelaer, P., Carrera, V. H., Swift, S. L., Drachen, T., Raatz, H., Ryder, S., et al. (2020) · Health Technology Assessment · doi:10.3310/hta24510 · Cited by 19
Chang, J.-Y. A., Wang, C., Kang, H.-C., Shen, L., & Huang, C. (2017) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzx109 · Cited by 19
Stevanović, J., de Jong, L. A., Kappelhoff, B. S., Dvortsin, E., Voorhaar, M., & Postma, M. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163550 · Cited by 17
Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease
Febres, L. M. S., & Manteca, J. C. (2017) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2017.01.010 · Cited by 11
Jugrin, A. V., Hösel, V., Ustyugova, A., Francesco, M. D., Lamotte, M., & Sunderland, T. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1078340 · Cited by 10
Self-citationIsolated distal deep vein thrombosis: Diagnosis and management
Tang, Y., Luo, Z., & Ye, X. (2025) · Science Progress · doi:10.1177/00368504251364934 · Cited by 6
“…comparable VTE recurrence prevention between dabigatran etexilate and rivaroxaban, with dabigatran exhibiting superior cost-effectiveness (lower total costs: £8242/QALY vs £10,075/QALY for warfarin over 24 months 74 ) due to reduced clinically relevant bleeding events and higher QALY gains.”
Miki, N., Inoue, S., Shibahara, H., Kurazono, K., Perard, R., & Tateishi, R. (2021) · JGH Open · doi:10.1002/jgh3.12597 · Cited by 3
Νεότερα από του στόματος αντιπηκτικά και αιμοραγίες σε ειδικές κατηγορίες
Ράμναλη, Α. Χ. (2020) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.9186
Metadata
- Authors
- Jugrin, A. V., Ustyugova, A., Urbich, M., Sunderland, T., & Lamotte, M.
- Affiliations
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (United Kingdom) (GB)
- Corresponding author
- Lamotte, Mark
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2015
- Volume
- 114
- Issue
- 10
- Pages
- 778-792
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2163451556
- Cited by
- 11
- References
- 25
- Citations by year
- 2025: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2017: 3 · 2016: 2 · 2015: 1
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim International GmbH
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- dabigatran etexilate, warfarin, venous thromboembolism, deep vein thrombosis, pulmonary embolism, long-term anticoagulation, cost-utility analysis, quality-adjusted life years, cost per QALY, bleeding risk, anticoagulation, National Health Service costs
- MeSH terms
- Dabigatran, Acute Disease, Anticoagulants, Cost-Benefit Analysis, Drug Administration Schedule, United Kingdom, Hemorrhage, Humans, Pulmonary Embolism, State Medicine, Time Factors, Warfarin, Drug Costs, Treatment Outcome, Models, Economic, Quality-Adjusted Life Years, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.